

# GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: **Stock**

## Company

2024/05/17 17:35:30

# GRIFOLS

Price

**9.89** EUR

Difference ▼ -0.64% (-0.06)

## Contact Details

GRIFOLS SA

Tel:  
+34-93-571-02-21

--

Fax:  
+34-93-571-02-67

Avinguda de la Generalitat, 152-158,  
Parc de Negocis Can Sant Joan  
08174 Barcelona

Web:  
<http://www.grifols.com>

E-mail: -



## Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 6,451,905,000  |                        | 4,653,587,000  |                        | 5,510,280,000  |                        |
| <b>Common stock capital</b>           |                | 119,604,000            |                | 119,604,000            |                | 119,604,000            |
| <b>Fixed assets</b>                   | 15,002,765,000 |                        | 17,007,730,000 |                        | 13,801,384,000 |                        |
| <b>Equity capital of a company</b>    |                | 7,972,485,000          |                | 8,457,544,000          |                | 8,147,035,000          |
| <b>Cash and cash equivalents</b>      | 529,577,000    |                        | 547,979,000    |                        | 655,493,000    |                        |
| <b>Accrued liabilities</b>            |                | 116,925,000            |                | 110,063,000            |                | 24,122,000             |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 2,315,604,000          |                | 1,955,847,000          |                | 3,474,312,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 11,152,774,000         |                | 11,232,803,000         |                | 7,675,281,000          |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 814,080,000            |                | 891,725,000            |                | 9,222,000              |
| <b>Total assets</b>                   | 21,454,670,000 | 21,454,670,000         | 21,661,317,000 | 21,661,317,000         | 19,311,664,000 | 19,311,664,000         |

## Balance notes

|                            | 2023    | 2022    | 2021   |
|----------------------------|---------|---------|--------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS   |
| <b>Employees</b>           | 23,744  | 26,326  | 23,245 |
| <b>Equity ratio</b>        | 47.16%  | 49.79%  | 52.80% |
| <b>Debt-equity ratio</b>   | 112.05% | 100.84% | 89.38% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 26.89% | 34.76% | 29.90% |

# GRIFOLS SA

ISIN: ES0171996087 WKN: - Asset Class: **Stock**

## Income statement

|  | 2023          | 2022          | 2021          |
|--|---------------|---------------|---------------|
| <b>Turnover</b>  | 6,591,977,000 | 6,063,967,000 | 4,933,118,000 |
| <b>Net income</b>  | 59,315,000    | 208,279,000   | 182,803,000   |
| <b>EBIT</b>  | 732,630,000   | 747,110,000   | 569,789,000   |
| <b>Operating income before taxes</b>                                 | 161,200,000   | 259,261,000   | 284,710,000   |
| <b>Cash Flow</b>   | 208,283,000   | -150,000      | 608,423,000   |
| <b>Net interest income</b>   | -571,430,000  | -487,849,000  | -285,079,000  |
| <b>Research and development expenses</b>                             | 330,551,000   | 316,845,000   | 299,570,000   |
| <b>Income taxes</b>  | 43,349,000    | 90,111,000    | 85,126,000    |
| <b>Result from investments in subsidiaries, associates and other</b> | 62,818,000    | 101,996,000   | 65,743,000    |
| <b>Revenues per employee</b>   | 277,627       | 230,341       | 212,223       |

## Board of Directors

|                               |                               |
|-------------------------------|-------------------------------|
| Thomas Heinrich Glanzmann     | Chairman of Supervisory Board |
| Enriqueta Felip Font          | Member of Supervisory Board   |
| Albert Coma-Cros              | Member of Supervisory Board   |
| Carina Szpilka Lázaro         | Member of Supervisory Board   |
| James Costos                  | Member of Supervisory Board   |
| Montserrat Muñoz Abellana     | Member of Supervisory Board   |
| Raimon Grifols Roura          | Member of Supervisory Board   |
| Susana González Rodríguez     | Member of Supervisory Board   |
| Tomás Dagá Gelabert           | Member of Supervisory Board   |
| Victor Grifols Deu            | Member of Supervisory Board   |
| Íñigo Sánchez-Asiain Mardones | Member of Supervisory Board   |

## Members of Management Board

|                      |                               |
|----------------------|-------------------------------|
| Thomas Glanzmann     | Chairman of Managing Board    |
| Raimon Grifols Roura | Member of Executive Committee |
| Victor Grifols Deu   | Member of Executive Committee |